
Semba Biosiences Inc (AKA: Semba Biosciences~Semba Inc) Profile last edited on: 2/3/22
CAGE: 4C2Z2
UEI: YF3SDHLN3J75
Business Identifier: Bench top continuous chromatography systems Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Dane
Congr. District: 02
County: Dane
Public Profile
Semba Biosciences Inc. is a life science company whose principals pioneered development of bench top continuous chromatography systems for efficient and scalable purification of biomolecules. The companyâs lab-scale Octave® Systems are used in the food, chemical, and pharmaceutical industries worldwide. The new ProPD⢠and ProGMP⢠products bring the power of continuous chromatography to the biopharmaceutical industry for downstream process development and single-use manufacturing. In late 2018, it was announced that Tosoh Bioscience LLC had completed a significant-sized equity investment in Semba Biosciences with the intention of acquiring full ownership. Tosoh Bioscience is a subsidiary of Tosoh Corporation in Japan, the parent of the Tosoh Group that is made up of over 100 companies worldwide. With a history of teaming and collaborating with Tosoh Bioscience on various biomanufacturing projects since 2007 - described as anchored inthe fact that the technologies of the two entities are a very good fit - this latest endeavor is expected to provide an integrated solution for bioprocess research, development and continuous manufacturing offer customers the most advanced platform for multicolumn continuous biochromatography. Consistent with what they had annaounced at the time of their initial investment in Semba Biosciences - an innovator in the field of multi-column chromatography (MCC) instrumentation and technology for downstream purification of biologics - in October 2021 it was announced that the firmis now wholly owned by Tosoh Bioscience. Paties to the transaction indicated that combining Semba Biosciencesâ advanced Simulated Moving Bed (SMB) technology with Tosoh Bioscienceâs best-in-class resins, the new entity wil be able to offer unparalleled efficiency and productivity in downstream processes and significantly decrease the cost of manufacturing. Tosoh Bioscience - located in King of Prussia, PA., - indocated intent to expand Semba team in M
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2015 | 2 | NIH | $1,707,219 | |
Project Title: Continuous Chromatography Device to Economically Purify Clinical-Grade Antibodies | ||||
2007 | 1 | NIH | $107,650 | |
Project Title: Novel Simulated Moving Bed Chromatography Device to Purify Recombinant Proteins |
Key People / Management
Robert Mierendorf -- President & CEO
Lisa Anderson
Anthony C Grabski -- Director of Research and Development
Brian Harbrecht -- Director of Engineering
Lisa Johnson -- Chief Business Officer
Anil Oroskar -- Founder
Lisa Anderson
Anthony C Grabski -- Director of Research and Development
Brian Harbrecht -- Director of Engineering
Lisa Johnson -- Chief Business Officer
Anil Oroskar -- Founder
Company News
Oct
19
2009
|
Simulated Moving Bed Chromatography |